Fenwick represented Metagenomi, a next-generation gene-editing company launched by UC Berkeley scientists in 2018, in its $65 million Series A financing round. The round was led by Leaps by Bayer and Humboldt Fund. Other investors included Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital.
Metagenomi plans to use the Series A funding to accelerate the expansion of its gene editing systems for potential therapeutic use. More information can be obtained from Metagenomi’s announcement.
The Fenwick transaction team included corporate partners Matthew Rossiter and Ryan Slunaker and associates Alina Azizian, Noah Johnson, Han Ko and Joanna Xu.